Liquid formulations comprising anti-CD38 antibodies

The present invention provides a pharmaceutical composition comprising an anti-CD38 antibody at a concentration of about 15 to 40 mg/mL, sorbitol or mannitol at a concentration of about 20 to 30 mg/mL, a histidine-histidine salt buffer at a concentration of about 5 to about 28 mM, sodium chloride at a concentration of about 2 to 5 mg/mL, and Tween 20 or Tween 80 at a concentration of about 0.1 to 1 mg/L; wherein the anti-CD38 antibody is a Darumumab (Darumumab), and the anti-CD38 antibody is a Darumumab. 本发明提供了一种药物组合物，其包含浓度为约15～40mg/mL的抗CD38抗体，浓度为约20～30mg/mL的山梨醇或甘露醇，浓度为约5～约28mM的组氨酸-组氨酸盐缓冲液，浓度为约2～5mg/mL的氯化钠，浓度为约0.1～1mg/L的吐温20或吐温80；其中所述抗CD38抗体为达雷木单抗(Daratumumab)。